Advertisement

Biomodulation in Head and Neck Carcinomas: Therapeutic Approaches in Europe

  • Jan Eskandari
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 339)

Abstract

Biomodulation, especially in head and neck carcinomas (H & N Ca.)/ refers to both cytotoxic drugs and ionizing radiations activities. Due to the heterogeneity of the tumor cells, modulation would address just as well to hypoxic cells as to therapeutically induced resistant cells.

Keywords

Complete Remission Oral Mucositis Neck Carcinoma Double Strand Break Advance Squamous Cell Carcinoma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    T.H. Loeffler, J. Lindemann, H. Luckhaupt et al.,Chemotherapy of Advanced and Relapsed Squamous Cell Cancer of the Head and Neck with Split-dose Cisplatinui, 5-Fluorouracil and Leucovorin, Adv.Exp.Med.BioL 244: 269 (1988).Google Scholar
  2. 2.
    A. Caty, J. Lefebvre, X. Mirabel et al., Induction Chemotherapy by a Combination of 5-FU-Cisplatinum-Folinic Acid in Advanced Head and Neck Squamous Cell arcinoma, Pro.ASCO 11 Abst.793(1992).Google Scholar
  3. 3.
    H. Guaraldi, A. Martoni, A, Tononi et al., 5-Fluorouracil + Folinic Acid with Cisplatinum and Bleomycin in the Treatment of Advanced Head and Neck Squamous Cell Carcinoma, Ann. Onc. 2: 379 (1991).Google Scholar
  4. 4.
    A, Bensmaine, E. Tellez-Bernai, T. Guillot et al., Chimiothérapie Néoadjuvante par CDDP, 5-FU, Acide Folinique et Vindésine (Perfusion Continue) dans les Carcinomes ORL localement avancés, Bull. Cancer 79: 558 (1992).Google Scholar
  5. 5.
    A. Dreyfuss, J.R Clark, J.E. Wright et al., Continuous Infusion High-Dose Leucovorin with 5-Fluorouracil and Cisplatin for Untreated Stage IV Carcinoma of the Head and Neck, Ann. Int. Med. 112: 167 (1990).PubMedGoogle Scholar
  6. 6.
    E.E. Vokes, R.L. Schilsky, R.R. Weichselbaum et al., Induction Chemotherapy with Cisplatin, Fluorouracil and High-Dose Leucovorin for Locally Advanced Head and Neck Cancer: A Clinical and Pharmacologic Analysis, J. Clin. Oncol. 8: 241 (1990).PubMedGoogle Scholar
  7. 7.
    G. Fountzilas, J. Daniilidis, K.S. Sridhar et al., Induction Chemotherapy with a New Regimen Alternating Cisplatin, Fluorouracil with Mitomycin, Hydroxyurea and Bleomycin in Carcinomas of Nasopharynx or Other Sites of the Head and Neck Region, Cancer 66: 1453 (1990).PubMedCrossRefGoogle Scholar
  8. 8.
    G. Fountzilas, P. Kosmidis, P. Makrentonakis et al., Carboplatin Continuous Infusion 5- Fluoro uracil and Mid-Cycle High-Dose Methotrexate as Initial Treatment in Patients with Locally Advanced Head and Neck Cancer, Tumori 77: 426 (1991).PubMedGoogle Scholar
  9. 9.
    H. Boussen, E. Cvitkovic, J.L. Wendung et al., Chemotherapy of Metatstatic and/or Recurrent Undifferenciated Nasopharyngeal Carcinoma with Cisplatin, Bleomycin and Fluorouracil, J.Clin. Oncol. 9: 1675 (1991).Google Scholar
  10. 10.
    G. Forni, M. Giovarelli, A. Santoni, A Lymphokine-Activated Tumor Inhibition in vivo. The Local Administration of Interleukin-2 Triggers Nonreactive Lymphocytes from Tumor-bearing Mice to Inhibit Tumor Growth, J.Immunol. 134: 1305 (1985).PubMedGoogle Scholar
  11. 11.
    G. Forni, H. Fujiwara, F. Martino et al., Helper Strategy in Tumor Immunology: Expansion of Helper Lymphocytes and Utilization of Helper Lymphokines for Experimental and Clinical Immunotherapy, Cancer Met. Rev. 7: 289 (1988).Google Scholar
  12. 12.
    G. Cortesina, A. de Stefani, M. Giovarelli et al., Treatment Recurrent Squamous Cell Carcinoma of the Head and Neck with Low Doses of Interleukin-2 Injected Perilymphatically, Cancer 62: 2482 (1988).PubMedCrossRefGoogle Scholar
  13. 13.
    G. Cortesina, A. de Stefani, E. Galeazzi et al., The Effect of Preoperative Local Interleukin-2(IL-2) Injections in Patients with Head and Neck Squamous Call Carcinoma, Acta Oto-Lar. 111: 428 (1991).CrossRefGoogle Scholar
  14. 14.
    G. Cortesina, A. De Stefani, E. Galeazzi et al., Interleukin-2 Injected around Tumor-Draining Lymph Nodes in Head and Neck Cancer, Head-Neck 13 /2: 125 (1991).PubMedCrossRefGoogle Scholar
  15. 15.
    M. Squadrelli-Saraceno, L. Rivoltini, G. Cantu et al., Local Adoptive Immunotherapy of Advanced Head and Neck Tumors with Lak Cell and Interleukine-2, Tumori 76: 566 (1990).PubMedGoogle Scholar
  16. 16.
    V. Mattijssen, P. H. De Mulder, J. H. Schornagel et al., Clinical and Immunopathological Results of a Phase II Study of Perilymphatically Injected Recombinant Interleukin-2 Locally for Advanced, Nonpretreated Head and Neck Squamous Cell Carcinoma, J. Iim. 10: 63 (1991).Google Scholar
  17. 17.
    P. Musiani, E. De Campora, S. Valitutti, Effect of Low Doses of Interleukin-2 Injected Perilymphatically and Peritumorally in Patients with Advanced Primary Head and Neck Squamous Cell Carcinoma, J. Biol. Resp. Mod 8: 571 (1989).Google Scholar
  18. 18.
    P.J. Cohen, M.T. Lotze, J.R. Roberts et al., The Immunopathology of Sequential Tumor Biopsies in Patients Treated with Interleukin-2, Am. J. Pathol. 129: 208 (1987).PubMedGoogle Scholar
  19. 19.
    G. Melioli, G. Margarino, M. Scala et al., Perilymphatic Injections of Recombinant Interleukin-2 (rIL-2) Partially Correct the Immunologic defects in Patients with Advanced Head and Neck Squamous Cell Carcinoma, Laryngo. 102 /5: 572 (1992).CrossRefGoogle Scholar
  20. 20.
    S. Toma, M. Benasso, M. Merlano et al., Concomittant Cisplatin and Recombinant Interferon alpha-2b in Head and Neck Cancer, Drug Invest. 3: 341 (1991).CrossRefGoogle Scholar
  21. 21.
    A. Bensmaine, N. Azli, F. Janot et al., Etude de la faisabilité de l’Association 5-FU-CDDP-Interféron (IFN alpha 2b) dans les Récidives et/ou Métastases des Carcinomes Epidermoides de la Tête et du Cou, Bull. Cancer 79: 559 (1992).Google Scholar
  22. 22.
    E.E. Vokes, M.J. Ratain, R. Mick et al., A Clinical Pharmacologie Phase I-II Study of PFL with Interferon alpha-2b (IFN) for Head and Neck Cancer (HNC), Pro.ASCO 11 Abst. 782 (1992).Google Scholar
  23. 23.
    M.E. Gore, P. Riches, K.A. MacLennan et al., Intra-Arterial Interleukin-2 in Squamous Cell Carcinoma of the Head and Neck, Pro. ASCO 11 Abst. 814 (1992).Google Scholar
  24. 24.
    B. Fiorentino, C. Amatetti, P. di Stefano et al., Weekly Sequential Administration of Interferon-alpha-2b (IFNa-2b) and Interleukin-2 (IL-2) in Patients with Advanced Malignancies, Pro. ASCO. 11 Abst. 835 (1992).Google Scholar
  25. 25.
    F. Geara, T.A. Girinski, N. Chavaudra et al., Estimation of Clonogenic Cell Fraction in Primary Culture Derived from Human Squamous Cell Carcinomas, Int. J. Rad. Oncol. Biol. Phys. 21: 661 (1991).CrossRefGoogle Scholar
  26. 26.
    J.F. Fowler, The Phantom of Tumor Treatment-Continually Rapid Proliferation Unmasked, Rad.Oncol 22: 156 (1991).CrossRefGoogle Scholar
  27. 27.
    J.F. Fowler, Apparent Rates of Proliferation of Acutely Responding Normal Tissues during Radiotherapy of Head and Neck Cancer, Int. J. Rad. Oncol. Biol. Phys. 21: 1451 (1991).CrossRefGoogle Scholar
  28. 28.
    S.M. Bentzen, H.D. Thames, Clinical Evidence for Tumor Clonogen Regeneration: Interpretations of the Data, Rad.Oncol. 22: 161 (1991).CrossRefGoogle Scholar
  29. 29.
    K.R. Trott, J. Kummermehr, Accelerated Repopulation in Tumours and Normal Tissues, Rad. Oncol. 22: 159 (1991).Google Scholar
  30. 30.
    G. Sanguinetti, R. Corvo, E. Accomando et al., Accelerated Hyperfractionated (Concomitant Boost) Radiotherapy for Head and Neck Carcinomas: Preliminary Results, 3rd Int. Conf. on H & N Ca., San Francisco, California (July 26–30 1992 ).Google Scholar
  31. 31.
    S.H. Bentzen, L.V Johansen, J, Overgaard et al., Clinical Radiobiology of Squamous Cell Carcinoma of the Oropharynx, Int. J. Rad. Oncol. Biol. Phys. 20: 1197 (1991).CrossRefGoogle Scholar
  32. 32.
    G. Wiernick, C.J. Alcock, T.D. Bates et al., Final Report on the Second British Institute of Radiology Fractionation Study: Short versus Long overall Treatment Times for Radiotherapy of Carcinoma of the Laryngo-Pharynx, Br. J. Radiol. 64: 232 (1991).CrossRefGoogle Scholar
  33. 33.
    J.C. Horiot et al., Hyperfractionated compared with Conventional Radiotherapy in Oropharyngeal Carcinoma: an EORTC Randomized Trial, Int. J. Radiat. Oncol. Biol. Phys. 26: 779 (1990).Google Scholar
  34. 34.
    L.H. Pinto, P.C.V. Canary, C.H.H. Araujo et al., Prospective Randomized Trial Comparing Hyperfractionated versus Conventional Radiotherapy in Stages III and IV Oropharyngeal Carcinoma, Int. J. Rad. Oncol. Biol. Phys. 21: 557 (1991).CrossRefGoogle Scholar
  35. 35.
    F. Sanchiz, A. Milla, J. Torner et al., Single Fraction per Day versus Two Fractions per Day versus Radiochemotherapy in the Treatment of Head and Neck Cancer, Int. J. Rad. Oncol. Biol. Phys. 19: 1347 (1990).CrossRefGoogle Scholar
  36. 36.
    A.C. Begg, I. Hofland, M. Van Glabbeke et al., Predictive Value of Potential Doubling Time for Radiotherapy of Head and Neck Tumor Patients: Results from the EORTC Cooperative Trial 22851, Sem. Radiat.Oncol. 2: 1 (1992).Google Scholar
  37. 37.
    E. Geido, W. Giaretti, R. Corvo et al., Cell Kinetics by in vivo Bromodeoxyuridine and Flow Cytometry for the Radiotherapy Planning of Head and Neck Tumors, 3rd Int.Conf. on H & N Ca., San Francisco, California (July 26–30 1992 ).Google Scholar
  38. 38.
    M.I. Saunders, S. Dische, E.J. Grosch et al., Experience with CHART, Int. J. Radiat. Oncol. Phys. 21: 871 (1991).CrossRefGoogle Scholar
  39. 39.
    J. Overgaard, H. Sand, A.P. Andersenet ah, Misonidazole Combined with Split-course Radiotherapy in the Treatment of Invasive Carcinoma of Larynx and Pharynx. Report from the DAHANCA 2 Study, Int. J. Radiat. Oncol. Biol. Phys. 16: 1065 (1989).PubMedCrossRefGoogle Scholar
  40. 40.
    C.N. Coleman, L. Noll, N.Riese et al., Final Report of the Phase I Trial of Continuous Infusion Etanizadole (SR 2508): a Radiation Therapy Oncology Group Study, Int. J. Radiat. Oncol. Biol. Phys. 22: 577 (1992).PubMedCrossRefGoogle Scholar
  41. 41.
    D. Chassagne, I. Charreau, H. Sancho-Garnier et al., First Analysis on Tumor Regression for the European Randomized Trial of Etanizadole Combined with Radiotherapy in Head and Neck Carcinomas, Int. J. Radiat. Oncol. Biol. Phys. 22: 581 (1992).PubMedCrossRefGoogle Scholar
  42. 42.
    J. Overgaard, H. Sand-Hassen, B. Lindelov et al., Nimorazole as a Hypoxic Radiosensitizer in the Treatment of Supraglottic, Larynx and Pharynx Carcinoma. First Report from the DAHANCA protocol 5–85, Radiother. Oncol. 20: 143 (1990).Google Scholar
  43. 43.
    D.J. Honess, N.M. Bleehen, Effects of Calcium Channel Blockers on Renal Function in Mice, Int. J. Radiat. Oncol. Biol. Phys. 22: 443 (1992).PubMedCrossRefGoogle Scholar
  44. 44.
    M.R. Horsman, P.E.G. Kristjansen, M. Mizuno et al., Biochemical and Physiological Changes Induced by Nicotinamide in a C3H Mouse Mammary Carcinoma and CDF1 Mice, Int. J. Radiat. Oncol. Biol. Phys. 22: 451 (1992).PubMedCrossRefGoogle Scholar
  45. 45.
    K. Skov, S. MacPhail, Interaction of Platinum Drugs with Clinically Relevant X-Ray Doses in Mammalian Cells: a Comparison of Cisplatin, Carboplatin, Iproplatin and Tetraplatin, Int. J. Radiat. Oncol. Biol. Phys. 20: 221 (1991).PubMedCrossRefGoogle Scholar
  46. 46.
    P. Lamblin, P. Scalliet, B. Coster et al., Influence of Cisplatinum on Intestinal Tolerance to Photon and Neutron Irradiation in Mice, (to be published 1992 ).Google Scholar
  47. 47.
    J.M. Bachaud, J.M. David, G. Boussin et al., Combined Postoperative Radiotherapy and Weekly Cisplatin Infusion for Locally Advanced Squamous Cell Carcinoma of the Head and Neck: Preliminary Report of a Randomized Trial, Int. J. Radiat. Biol. Phys. 20: 243 (1991).CrossRefGoogle Scholar
  48. 48.
    M. Busch, E. Dühmke, Longtime Impact of Low Dose Cisplatinum and Accelerated Fractionation of Radiotherapy of Head and Neck Cancer, Pro; ASCO. 11 Abst. 789 (1992).Google Scholar
  49. 49.
    P. Volling, S. Starr, Carboplatin Plus Radiation Therapy in Head and Neck Cancer, Sem. Oncol. 18: 17 (1991).Google Scholar
  50. 50.
    M. Airoldi, V. Brando, G. Cortesina et al., Simultaneous Radiation Therapy (RT) and Chemotherapy (CT) with Carboplatin (CBDCA) for Locally Unresectable Stage III-IV Head and Neck Cancer (HNC), Pro. ASCO. 11 Abst. 805 (1992).Google Scholar
  51. 51.
    R. Orecchia, G.L. Sannazzari, M. Airoldi et al., Daily Carboplatin (CBDCA) and Standard Radiation Therapy (RT) in Inoperable Head and Neck Cancer (HNC): a Dose-Finding Study, Pro. ASCO. 11 Abst. 795 (1992).Google Scholar
  52. 52.
    A. Testolin, F. Pozza, F. Bagatella et al., Combined Treatment for Locally Advanced Carcinoma of Head and Neck. Preliminary Results of a Randomized Trial: Cisplatin (CP) vs Carboplatin (CBP) and Concomittant Radiotherapy (RT), Pro. ASCO. 11 Abst. 794 (1992).Google Scholar
  53. 53.
    T.C. Lo, A.L. Wiley, F.J. Ansfield, Combined Radiation Therapy and 5-Fluorouracil for Advanced Squamous Cell Carcinoma of the Oral Cavity and Oropharynx: a Randomized Study, Am. J. Roentgenol. 126: 229 (1976).Google Scholar
  54. 54.
    T.S. Lawrence, D.K. Heimburger, D.S. Shewach, The Effects of Leucovorin and Dipyridamole on Fluoropyrimidine-Induced Radiosensitization, Int. J. Radiat. Oncol. Biol. Phys. 20: 377 (1991).PubMedCrossRefGoogle Scholar
  55. 55.
    K.J. Scanlon, H. Kashani-Sabet, Elevated Expression of Thymidylate Synthase Cycle Genes in Cisplatin-Resistant Human Ovarian Carcinoma A2780 Cells, Proc. Natl. Acad. Sci. USA 85: 650 (1988).PubMedCrossRefGoogle Scholar
  56. 56.
    J. Eskandari, H. de Muizon, D. Bonnet et al., 5-Fluorouracil-Leucovorin and Concomittant Radiotherapy in Advanced Head and Neck Carcinomas: a Phase I Study, Pro. ASCO. 11 Abst. 791 (1992).Google Scholar
  57. 57.
    W. Dobrowsky, E. Dobrowsky, H. Strassl et al., Response to Preoperative Concomittant Radio-chemotherapy with Mitomycin C and 5-Fluorouracil in Advanced Head and Neck Cancer, Eur. J. Cancer. Clin. Oncol. 25: 845 (1989).PubMedCrossRefGoogle Scholar
  58. 58.
    D. Gandia, P. Wibault, P. Harandas, Radiochimiothérapie Simultanée (RS) dans les récidives Locorégionales des Cancers Epidermoïdes de la Tête et du Cou (CETC), Bull. Cancer 79: 558 (1992).Google Scholar
  59. 59.
    M. Merlano, M. Benasso, H. Cavallari et al., Combined Chemotherapy and Radiation Therapy in Advanced Inoperable Squamous Cell Carcinoma of the Head and Neck, Cancer 67: 915 (1991).PubMedCrossRefGoogle Scholar
  60. 60.
    T.G. Wendt, R.C. Hartenstein, T.P.U. Wustrow, Cisplatin, Fluorouracil with Leucovorin Calcium Enhancement, and Synchronous Accelerated Radiotherapy in the Management of Locally Advanced Head and Neck Cancer: a Phase I Study, J. Clin. Oncol. 7: 471 (1989).PubMedGoogle Scholar
  61. 61.
    M.J. Evans, C.J. Kovacs, J.M. Gooya et al., Interleukin-I alpha Protects against the Toxicity Associated with Combined Radiation and Drug Therapy, Int. J. Radiat. Oncol. Biol. Phys. 20: 303 (1991).PubMedCrossRefGoogle Scholar
  62. 62.
    C.J. Kovacs, J.M. Gooya, J.P. Harrell et al., Altered Radioprotective Properties of Interleukin I alpha (IL-1) in Non-Hematologic Tumor-Bearing Animals, Int. J. Radiat. Oncol. Biol. Phys. 20: 307 (1991).PubMedCrossRefGoogle Scholar
  63. 63.
    G.J. Peters, C.L. van der Wilt, F. Gyergyay et al., Protection by WR-2721 of the Toxicity Induced by the Combination of Cisplatin and 5-Fluorouracil, Int. J. Radiat. Oncol. Biol. Phys. 22: 785 (1992).PubMedCrossRefGoogle Scholar
  64. 64.
    J.F. Ensley, J.R. Jacobs, A. Weaver et al., The Correlation between Response to Cisplatinura Combination Chemotherapy and Subsequent Radiotherapy in Previously Untreated Patients with Advanced Squamous Cells Cancers or the Head and Neck, Cancer 54: 811 (1984).PubMedCrossRefGoogle Scholar
  65. 65.
    C.M.J. De Pooter, P.G. Scalliet, H.J. Elst et al., Resistance Patterns between Cisdi-amminedichloroplatinum(II) and Ionizing Radiation, Cancer Research 51: 4523 (1991).PubMedGoogle Scholar
  66. 66.
    W.C.M. Dempke, L.K. Hosking, B.T, Hill, Expression of Collateral Sensitivity to Cisplatin, Methotrexate, and Fluorouracil in a Human Ovarian Carcinoma Cell Line Following Exposure Fractionated X-Irradiation in vitro, Sem. Oncol. 19: 66 (1992).Google Scholar
  67. 67.
    C. Jaulerry, J. Rodriguez, F. Brunin et al., Induction Chemotherapy in Advanced Head and Neck Tumors: Results of two Randomized Trials, Int. J. Radiat. Oncol. Biol. Phys. 23: 483 (1992).PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1993

Authors and Affiliations

  • Jan Eskandari
    • 1
  1. 1.OncologyMarseilleFrance

Personalised recommendations